Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Feb 18.

Published in final edited form as: Eur J Pharmacol. 2001 Jan 19;412(1):13–20. doi: 10.1016/s0014-2999(00)00941-9

Fig. 3. — Elk-1 activation and PD98059. The ability of no additions (□), 100 nM (FAFN)BB^6–14 (), 100 nM (FAFN)BB^6–14 + 10 μM PD98059 () and ras (□) to activate elk-1 was determined using a reporter gene construct. The relative luminometer intensity was determined. The mean value ± S.D. of two determinations is indicated. This experiment is representative of two others.

Inline graphic — Elk-1 activation and PD98059. The ability of no additions (□), 100 nM (FAFN)BB^6–14 (), 100 nM (FAFN)BB^6–14 + 10 μM PD98059 () and ras (□) to activate elk-1 was determined using a reporter gene construct. The relative luminometer intensity was determined. The mean value ± S.D. of two determinations is indicated. This experiment is representative of two others.

HHS Vulnerability Disclosure